HFM information and reviews
HFM
96%
Octa information and reviews
Octa
94%
FXCC information and reviews
FXCC
92%
FxPro information and reviews
FxPro
89%
FBS information and reviews
FBS
88%
Vantage information and reviews
Vantage
85%

Pfizer stock rockets after $43 billion acquisition of Seagen


27 March 2023

Pfizer (PFE) has announced that it will acquire Seagen for the sum of $43 billion (USD). The deal is expected to close in late 2023 or early 2024, pending regulatory approvals and other customary closing conditions, but that’s a long time away in the trading term. What can we expect to see on the charts in the coming months?

Who is Seagen?

Seagen is known for its antibody-drug conjugate (ADC) technology, which delivers potent drugs directly to cancer cells while sparing healthy tissues. Seagen has three approved products on the market: Adcetris, Padcev, and Tukysa. It also has a robust pipeline of more than 10 clinical-stage candidates across various types of cancers.

Pfizer said that the acquisition of Seagen would enhance its oncology portfolio and capabilities, as well as accelerate its revenue growth and earnings potential. But could such a purchase increase share value in 2023, since Pfizer itself only expects the deal to be accretive to its adjusted earnings per share by 2025?

Pfizer's CEO Albert Bourla said in a statement: "We are thrilled to welcome Seagen to the Pfizer family and believe that together we will transform the lives of millions of cancer patients around the world. Seagen's expertise in ADC complements our leadership in immuno-oncology and targeted therapies, creating an unrivaled opportunity to advance the science and deliver more breakthroughs for patients."

Until now, Pfizer has only focused on Covid vaccination, antibiotics, and supplements. Moving into the cancer treatment sector opens many doors for the company with a potential long-term supply/demand dynamic.

Seagen's CEO Clay Siegall said in a statement: "We are proud of what we have accomplished at Seagen over the past two decades and are excited to join forces with Pfizer to bring our innovative medicines to more patients globally. We share a common vision of discovering and developing transformative therapies for people with cancer."

How will Pfizer stock react to this news? Some analysts have expressed positive views on the deal. For example, Mizuho Securities analyst Vamil Divan said: "We view this as an attractive acquisition for Pfizer given Seagen's strong position in hematology/oncology. We also see significant synergies from combining Pfizer's global reach with Seagen's innovative pipeline."

Before Pfizer announced the Seagen acquisition on 13 March 2023, Pfizer's stock tanked due to an unexplainable selloff. After the acquisition news confirmed the offer of $229 (USD) per Seagen share, the market sentiment became strongly bullish, rising 7% to $40.65  within the first 5 hours. Now in a steady range rise, the latest retrace barely made it to the 0.236 of the Fibonacci, making it a strong bullish signal.

However, some investors may have concerns about the high price tag of the deal, which values Seagen at a premium of about 40% over its closing price on Friday. Some may also question whether Pfizer can integrate Seagen smoothly and efficiently without disrupting its operations. And of course, the looming recession is still a factor to consider.

Conclusion

Ultimately, the long-term impact of the deal will depend on how well Pfizer can leverage Seagen's assets and expertise to create value for its shareholders and customers. Covid was a convenient cash cow for the pharmaceutical giant, and now it is turning its sights on Cancer, and if it makes significant advances in treatments and success rates, the sky's the limit.

And while the joining of these two companies will be beneficial to millions over the coming years, Q2 traders might consider adding stochastic and RSI to their chart analysis when forecasting with technicals. A steady growth seems obvious, but increased trading volume from institutional investors may be sporadic, causing wild and unforeseeable volatility. Exness’ Stop Out Protection feature will significantly reduce risks, but Stop Loss is highly recommended for traders planning to leave orders open for multiple days or weeks.

#source

Share: Tweet this or Share on Facebook


Related

Fed stops dollar's CPI-related bleed, BoJ next
Fed stops dollar's CPI-related bleed, BoJ next

Dollar tumbles after weaker-than-expected CPI data. Recovers somewhat after Fed signals one rate cut. BoJ decision looms as investors bet on July hike. US CPI data propels Wall Street to fresh records.

13 Jun 2024

Dollar rallies on NFP, euro slips after EU vote
Dollar rallies on NFP, euro slips after EU vote

US nonfarm payrolls surge past expectations - Dollar skyrockets as Fed rate cuts are scaled back - Euro slips as Macron calls snap election in France - S&P 500 pulls back after hitting new record high

10 Jun 2024

Dollar rallies as market angst spreads
Dollar rallies as market angst spreads

Higher Treasury yields contribute to stock indices' retreat. Euro under pressure as the pound benefits from the election. Gold fails to benefit from risk-off while oil drops ahead of OPEC meeting.

30 May 2024

Dollar benefits from hawkish Fed minutes
Dollar benefits from hawkish Fed minutes

Dollar rallies as both gold and bitcoin fall. Early UK elections called after mixed UK CPI report. EZ PMIs unlikely to stop the ECB from cutting rates in June

23 May 2024

Dollar plummets as US data supports Fed rate cuts
Dollar plummets as US data supports Fed rate cuts

US inflation resumes downtrend, retail sales stagnate. Dollar falls as investors add to Fed rate cut bets. Yen gains even as Japanese economy contracts. Wall Street at fresh records, gold rallies on US data.

16 May 2024

US dollar recovers, stocks rally stalls as market tries to find its footing
US dollar recovers, stocks rally stalls as market tries to find its footing

Fed expectations drive the market. Three Fed speakers on the wires today. Dollar recovers but all eyes are on the US stocks and Treasury yields. Yen on the back foot again, gold steady amid the Israeli ground operation.

8 May 2024


Editors' Picks

The Top Forex Expert Advisors 2024: Performance, Strategy, and Reliability Review

An annual roundup reviewing the most successful Forex Expert Advisors (EAs) based on their performance, strategies employed, reliability, and user feedback. This piece would provide insights into which EAs have been market leaders and why.

The Evolution of Forex Expert Advisors: Navigating the Path of Technological Revolution

The concept of automated trading has been around for decades, but the accessibility and sophistication of Forex EAs have seen significant advancements in the past few years. Initially, automated trading systems were rudimentary, focusing on simple indicators like moving averages.

The Impact of EAs on Forex Trading: A Double-Edged Sword

By enabling continuous, algorithm-based trading, EAs contribute to the efficiency of the Forex market. They can instantly react to market movements and news events, providing liquidity and stabilizing currency prices through their high-volume trading activities.

MultiBank Group information and reviews
MultiBank Group
84%
XM information and reviews
XM
82%
FP Markets information and reviews
FP Markets
81%
FXTM information and reviews
FXTM
80%
AMarkets information and reviews
AMarkets
79%
BlackBull information and reviews
BlackBull
78%

© 2006-2024 Forex-Ratings.com

The usage of this website constitutes acceptance of the following legal information.
Any contracts of financial instruments offered to conclude bear high risks and may result in the full loss of the deposited funds. Prior to making transactions one should get acquainted with the risks to which they relate. All the information featured on the website (reviews, brokers' news, comments, analysis, quotes, forecasts or other information materials provided by Forex Ratings, as well as information provided by the partners), including graphical information about the forex companies, brokers and dealing desks, is intended solely for informational purposes, is not a means of advertising them, and doesn't imply direct instructions for investing. Forex Ratings shall not be liable for any loss, including unlimited loss of funds, which may arise directly or indirectly from the usage of this information. The editorial staff of the website does not bear any responsibility whatsoever for the content of the comments or reviews made by the site users about the forex companies. The entire responsibility for the contents rests with the commentators. Reprint of the materials is available only with the permission of the editorial staff.
We use cookies to improve your experience and to make your stay with us more comfortable. By using Forex-Ratings.com website you agree to the cookies policy.